GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Short-Term Capital Lease Obligation

Amplia Therapeutics (ASX:ATX) Short-Term Capital Lease Obligation : A$0.00 Mil (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Short-Term Capital Lease Obligation?

Amplia Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was A$0.00 Mil.

Amplia Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (A$0.00 Mil) to Mar. 2024 (A$0.08 Mil) but then declined from Mar. 2024 (A$0.08 Mil) to Sep. 2024 (A$0.00 Mil).

Amplia Therapeutics's annual Short-Term Capital Lease Obligation increased from Mar. 2022 (A$0.00 Mil) to Mar. 2023 (A$0.08 Mil) and increased from Mar. 2023 (A$0.08 Mil) to Mar. 2024 (A$0.08 Mil).


Amplia Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Amplia Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Short-Term Capital Lease Obligation Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Short-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.08 0.08

Amplia Therapeutics Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.08 - 0.08 -

Amplia Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


Amplia Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics Headlines

No Headlines